Treating patients with non-STEMI: Stent the culprit artery only or address all lesions?
Tóm tắt
Non-ST segment elevation myocardial infarction (non-STEMI) is a common presentation of the acute coronary syndrome (ACS) spectrum. Currently, the recommended treatment option is an invasive approach with angiography plus coronary revascularization to treat the culprit lesion. However, unlike in STEMI—in which the culprit lesion can be easily identified—in non-STEMI identifying the culprit lesion is difficult. Therefore, some have advocated for a more definitive approach to addressing all severe lesions in patients presenting with non-STEMI. The current European guidelines for percutaneous coronary intervention (PCI) for multivessel versus culprit-only stenting state that “the decision to perform either culprit vessel or complete revascularization can be made on an individual basis,” whereas the American College of Cardiology/American Heart Association guidelines for multivessel PCl in patients presenting with ACS recommend that “it be performed when there is a high likelihood of success and a low risk of morbidity and the vessels to be dilated subtend a moderate or large area of viable myocardium and have high risk by noninvasive testing.” Although lesions and coronary anatomies are each unique and the risk and benefit of coronary intervention to each lesion should be carefully examined, we recommend stenting the culprit lesion and other severe lesions after careful consideration, in a staged fashion if necessary. If the severity of nonculprit lesions is in question, fractional flow reserve or intravascular ultrasound should be considered.
Tài liệu tham khảo
Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002, 106:1893–1900.
Silber S, Albertsson P, Aviles FF, et al.: Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005, 26:804–847.
Bhatt DL: Diffuse coronary disease and atherothrombosis: a rationale for long-term therapy to prevent recurrent ischemic events. J Invasive Cardiol 2003, 15(Suppl B):3B–9B; discussion 9B–10B.
Bhatt DL: To cath or not to cath: that is no longer the question. JAMA 2005, 293:2935–2937.
Fuster V, Moreno PR, Fayad ZA, et al.: Atherothrombosis and high-risk plaque part I: evolving concepts. J Am Coll Cardiol 2005, 46:937–954.
Bhatt DL: Embolization—a pathological mechanism in renal artery stenosis. J Invasive Cardiol 2004, 16:196–197.
Shishehbor MH, Topol EJ, Mukherjee D, et al.: Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. Am J Cardiol 2006, 97:1585–1590.
Bhatt DL, Topol EJ: Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 2005, 112:906–915; discussion 923.
Buffon A, Biasucci LM, Liuzzo G, et al.: Widespread coronary inflammation in unstable angina. N Engl J Med 2002, 347:5–12.
Kornowski R, Mehran R, Satler LF, et al.: Procedural results and late clinical outcomes following multivessel coronary stenting. J Am Coll Cardiol 1999, 33:420–426.
Moussa I, Reimers B, Moses J, et al.: Long-term angiographic and clinical outcome of patients undergoing multivessel coronary stenting. Circulation 1997, 96:3873–3879.
Shishehbor MH, Lauer MS, Singh IM, et al.: In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? J Am Coll Cardiol 2007, 49:849–854.
Brener SJ, Murphy SA, Gibson CM, et al.: Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. Am J Cardiol 2002, 90:631–633.
Hlatky MA, Rogers WJ, Johnstone I, et al.: Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1997, 336:92–99.
Ijsselmuiden AJ, Ezechiels J, Westendorp IC, et al.: Complete versus culprit vessel percutaneous coronary intervention in multivessel disease: a randomized comparison. Am Heart J 2004, 148:467–474.
Kim SW, Hong MK, Lee CW, et al.: Multivessel coronary stenting versus bypass surgery in patients with multivessel coronary artery disease and normal left ventricular function: immediate and 2-year long-term follow-up. Am Heart J 2000, 139:638–642.
Bavry AA, Kumbhani DJ, Helton TJ, et al.: Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006, 119:1056–1061.
Bavry AA, Bhatt DL: Acute myocardial infarction and drug-eluting stents: a green light for their use or time for measured restraint? Am Heart J 2007, 153:719–721.
Rabbat MG, Bavry AA, Bhatt DL, Ellis SG: Understanding and minimizing late thrombosis of drug-eluting stents. Cleve Clin J Med 2007, 74:129–136.
Rioufol G, Finet G, Ginon I, et al.: Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002, 106:804–808.
Kelly P, Bhatt DL: Identification of vulnerable plaque—the quest continues. J Invasive Cardiol 2007, 19:55–57.
The Bypass Angioplasty Revascularization Investigation (BARI) Investigators: Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet 1993, 341:573–580.
CABRI Trial Participants: First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). Lancet 1995, 346:1179–1184.
The Bypass Angioplasty Revascularization Investigation (BARI) Investigators: Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996, 335:217–225.
The EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998, 352:87–92.
The Bypass Angioplasty Revascularization Investigation (BARI) Investigators: Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000, 35:1122–1129.
Glaser R, Selzer F, Faxon DP, et al.: Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 2005, 111:143–149.